Structural pharmacological studies on EGFR T790M/C797S.

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Drug resistance in EGFR-mutated non-small cell lung cancer (NSCLC) is a significant clinical challenge.
• Third-generation irreversible EGFR inhibitors are effective against T790M mutations but fail with the C797S resistance mutation.
• Development of novel reversible inhibitors is crucial to overcome emerging resistance mechanisms.

Purpose of the Study:

• To investigate the efficacy of Gö6976, a reversible inhibitor, against EGFR T790M and T790M/C797S mutations.
• To elucidate the structural basis of Gö6976 binding to EGFR wild-type, T790M, and T790M/C797S mutants.
• To provide insights for the development of next-generation EGFR inhibitors.

Main Methods:

• Co-crystallization and structural determination of EGFR T790M/C797S + Gö6976 and T790M + Gö6976 complexes.
• Enzyme kinetic assays for EGFR wild-type, T790M, and T790M/C797S.
• Analysis of structural and functional data to understand drug-target interactions.

Main Results:

• The C797S mutation minimally impacts EGFR kinase structure and function, but increases local hydrophilicity.
• Complex crystal structures reveal the binding mode of Gö6976 to EGFR, explaining its preference for the T790M mutant.
• Gö6976 demonstrates potential as a reversible inhibitor against EGFR resistance mutations.

Conclusions:

• The C797S mutation does not abolish EGFR kinase activity but alters the binding site characteristics.
• Gö6976's reversible binding mechanism offers an alternative to covalent inhibitors, bypassing C797S resistance.
• Structural and kinetic data provide a foundation for designing improved EGFR-targeted therapies for resistant NSCLC.